Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Once Weekly vs Twice Daily in Type 2 Diabetes (DURATION-5)
NCT00877890Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2009
- Primary completion
- Oct 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Mar 2009; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00877890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877890.